Document Detail


Perinatal corticosteroids: A review of research. Part I: Antenatal administration.
MedLine Citation:
PMID:  15077857     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The premature infant may receive therapeutic glucocorticoid drugs while in utero or in the postnatal period. This article (part I of a two-part series) discusses the benefits and risks of in utero, or antenatal, corticosteroids (ACS) for the premature infant. Part II addresses the benefits and risks of postnatal corticosteroid (PCS) use. There are numerous clinical studies on the therapeutic use of these steroids for the prevention of respiratory distress syndrome and chronic lung disease in the premature infant, although research results on the efficacy of repeated steroid exposure among premature infants vary. Premature infants who are exposed to repeated courses of ACS and/or high-cumulative-dose PCS may show no neurologic side effects until later in life. Research in newborn animal models focused on the timing, duration, and amounts of ACS and PCS. Current clinical research includes examination of the neurodevelopment of infants who are therapeutically exposed to perinatal corticosteroids, to identify safer minimal dose protocols. Over the past 30 years, corticosteroids have been increasingly prescribed before and after birth. Understanding the potential treatment benefits and risks to human fetuses and neonates is vital to clinical practice. This review presents historic and pharmacokinetic information about prenatal use of corticosteroids. It also offers scientific evidence of the benefits and risks identified in animal models and clinical trials, to stimulate thought that gtiides neonatal clinical practice.
Authors:
Isabell B Purdy; Dorothy J Wiley
Related Documents :
9160817 - Serum concentrations of cortisone and cortisol in premature infants.
12454897 - Prematurity at birth: trends, racial disparities, and epidemiology.
3839567 - Effect of bright light in the hospital nursery on the incidence of retinopathy of prema...
23185127 - Changes in oral feeding in preterm infants two weeks after hospital discharge.
11684107 - Care for adolescent pregnancy and childbirth.
8320607 - Effects of birth order, gender, and intrauterine growth retardation on the outcome of v...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Neonatal network : NN     Volume:  23     ISSN:  0730-0832     ISO Abbreviation:  Neonatal Netw     Publication Date:    2004 Mar-Apr
Date Detail:
Created Date:  2004-04-13     Completed Date:  2004-06-23     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8503921     Medline TA:  Neonatal Netw     Country:  United States    
Other Details:
Languages:  eng     Pagination:  15-30     Citation Subset:  N    
Affiliation:
UCLA School of Nursing, 700 Tiverton Avenue, Factor Building, Box 95619, Los Angeles, CA 90095-6919, USA. ibpurdy@ucla.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / therapeutic use*
Animals
Betamethasone / therapeutic use
Child Development
Dexamethasone / therapeutic use
Disease Models, Animal
Dose-Response Relationship, Drug
Female
Glucocorticoids / therapeutic use
Humans
Infant, Newborn
Neonatal Nursing / methods
Perinatal Care / methods*
Pregnancy
Respiratory Distress Syndrome, Newborn / drug therapy*,  nursing,  prevention & control*
Treatment Outcome
Grant Support
ID/Acronym/Agency:
NR0707 T32/NR/NINR NIH HHS
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Glucocorticoids; 378-44-9/Betamethasone; 50-02-2/Dexamethasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Osteogenesis imperfecta.
Next Document:  The discovery of retrolental fibroplasia and the role of oxygen: a historical review, 1942-1956.